Pfizer’s 2018 Global ASPIRE TTR Amyloidosis Competitive Grants Program
Pfizer is pleased to announce the 2018 Global ASPIRE Transthyretin (TTR) Amyloidosis Competitive Research Grant Awards for Junior Investigators. The Global ASPIRE TTR Amyloidosis program underscores Pfizer’s commitment to supporting investigators with an interest in advancing their academic research in TTR Amyloidosis.
Visit www.aspireresearch.org for more information.
The mission of the GLOBAL ASPIRE TTR Amyloidosis program is to support research in basic science and broad clinical research through a competitive grants program that advances medical knowledge in the understanding, diagnosis and treatment of TTR amyloidosis. In-scope research submissions along the entire clinical spectrum of TTR amyloidosis (from TTR familial amyloid polyneuropathy (TTR-FAP) to TTR cardiomyopathy) and including mixed phenotypes are highly encouraged.
Request for Proposals
Pfizer invites junior investigators with a terminal degree (MD and/or PhD and/or PharmD or equivalent) who are developing their research careers in TTR Amyloidosis to apply for the 2018 GLOBAL ASPIRE Awards in TTR amyloidosis through submission of innovative research proposals designed to further improve our understanding of the epidemiology, basic science and early diagnosis and treatment of TTR amyloidosis.
To be eligible for a GLOBAL ASPIRE TTR Amyloidosis award, applicants must:
- Have a professional terminal degree (MD and/or PhD and/or PharmD or equivalent). Applicants enrolled in a residency, fellowship or postdoctoral program are encouraged to apply.
- Be developing their research careers in TTR Amyloidosis.
- Be affiliated with a host institution.
- Have a mentor or senior investigator participate as a co-investigator.
Note: Members of the 2018 External Review Committee and 2017 ASPIRE awardees are not eligible to apply or serve as mentors or collaborating investigators on applications from other investigators (this includes applications from junior investigators).
Pfizer is funding awards ranging from $25,000 USD to a maximum of $50,000 USD each. All budgets must be submitted in USD and all awards will be paid in USD. Pfizer anticipates awarding up to 3 grants for the 2018 program. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
Independent, External Review Committee
Eligible proposals will be reviewed by an independent, external review committee comprised of medical and scientific experts. All reviews will be conducted on a blinded basis. Applicant identifying information will be redacted from submissions as required to protect and ensure the integrity of the blinded review process. Grants will be awarded based upon:
- Scientific merit of the research proposal
- Qualifications of the applicant
- Relevance of proposed research to the program’s mission
- Evidence of the applicant’s commitment to an academic research career
- Evidence of a suitable research environment
Applications must be received by 11:59pm EST on May 14, 2018. Late or draft submissions will not be accepted under any circumstances.
Program Details and Submission Instructions
For more information about this and other competitive research grant programs, please visit www.aspireresearch.org and click on 2018 ASPIRE TTR Amyloidosis.